Inhibikase Therapeutics (IKT) Cash & Equivalents (2020 - 2026)

Inhibikase Therapeutics (IKT) has 7 years of Cash & Equivalents data on file, last reported at $49.6 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $49.6 million, down 32.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $49.6 million (down 32.5% YoY), and the FY2025 annual result was $139.2 million, up 146.45% from the prior year.
• Cash & Equivalents fell to $49.6 million in Q1 2026 per IKT's latest filing, from $139.2 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $139.2 million in Q4 2025 and troughed at $913420.0 in Q3 2024.
• A 5-year average of $32.5 million and a median of $14.9 million in 2023 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2023 and 2025: Cash & Equivalents tumbled 94.09% in 2023, then soared 4089.72% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $7.2 million in 2022, then gained by 27.5% to $9.2 million in 2023, then soared by 516.36% to $56.5 million in 2024, then surged by 146.45% to $139.2 million in 2025, then slumped by 64.39% to $49.6 million in 2026.
• Business Quant data shows IKT's Cash & Equivalents at $49.6 million in Q1 2026, $139.2 million in Q4 2025, and $38.3 million in Q3 2025.